Loss of fragile histidine triad and amplification of 1p36.22 and 11p15.5 in primary gastric adenocarcinomas

Table 2 Amplification segments and the genes involved

Chr. region	Amp	Gain	SRO, bp (hg 18)	Size (kb)	Genes	Selected references
1p36.221	2	1	10 587 540-11 006 299	418.7	PEX14, CASZ1, C1orf127, TARDBP	N/A
1q21.2	1	3	148 737 723-149 062 575	324.9	TARS2, ECM1, ADAMTSL43, MCL13, ENSA2, GOLPH3L, HORMAD13, CTSS, CTSK, ARNT2	Gastric cancer[7], adenocarcinoma of the gastroesophageal junction[8]3, basal/luminal breast cancer[9]3, hepatocellular carcinoma[10]
8p23.1	2	3	10 475 239-10 562 632 10 681 251-10 943 920 11 250 228-11 887 602	87.4 262.7 637.4	RP1 L1PINX1, XKR6TDH, FAM167A, BLK, GATA4234, NEIL22, FDFT123, CTSB23	Gastric cancer[7,11], esophageal adenocarcinoma[12,13]3,[14],[15]3, adenocarcinomas of the gastroesophageal junction[16]3, small bowel adenocarcinoma[17]
8q24.21	1	11	128 331 422-128 837 626	506.2	POU5F1B, LOC727677, MYC23	Various cancer[5], esophageal adenocarcinoma[14], gastric cancer[18],[19]2,[20], papillary renal cell carcinoma[21]3
10q26.12	1	0	121 881 486-123 931 430	2050.0	PPAPDC1A, LOC283089, WDR11, FGFR23, ATE13, NSMCE4A3, TACC23	Breast cancer[22]3, gastric carcinoma[20]
10q26.13			126 212 750-126 362 686	149.9	LHPP, FAM53B
11p15.51	1	0	1 175 114-1 556 281	381.2	MUC5B, LOC255512, TOLLIP, BRSK2, HCCA2, DUSP8, LOC33865	N/A
11p13	2	1	34 675 094-35 068 916	393.8	APIP3, PDHX3	Breast cancer[23], gastric cancer cell line[24], head and neck squamous cell carcinoma cell line[25]3
11q13.2q13.3	3	0	68 912 663-69 256 388	343.7	CCND123, ORAOV123, FGF193	Various cancers[5], gastric cancer[7,11,20],[26]2, hepatocellular carcinoma[27]2, esophageal adenocarcinoma[14], esophageal and gastric cancer[26], esophageal squamous cell carcinoma[28]3, laryngeal/pharyngeal cancer[29]3
12p12.1	2	2	25 150 060-25 437 736	287.7	LRMP3, CASC1, LYRM5, KRAS23	Various cancers[5], esophageal adenocarcinoma[14], gastric cancer[11,20],[30]2, ovarian cancer[31]3
12q15	2	0	67 475 003-67 875 102 68 037 717-68 318 830	400.1 281.1	MDM22, CPMYEATS4 (GAS41)3, FRS23, CCT23, LRRC10	Various cancers[5], esophageal adenocarcinoma[14], gastric cancer[20,32], liposarcomas[33]3, melanoma cell line[34]3
17q12	2	1	35 000 176-35 150 077	149.9	NEUROD2, PPP1R1B2, STARD32, TCAP, PNMT2, PERLD12, ERBB22, C17orf37, GRB72	Various cancers[5], gastric cancer[11,20],[35-37]2,[38],[39]2
18q11.2	3	2	17 800 202-18 425 167	625.0	GATA634, CTAGE1	Pancreatic carcinoma[40,41]3, esophageal adenocarcinoma[14],[42]3
19q12	3	3	33 606 476-35 037 396	1340.9	LOC148145, LOC10050583, UQCRFS12, LOC284395, VSTM2B, POP42, PLEKHF12, C19orf122, CCNE12	Gastric cancer[43]2,[44],[45]2, esophageal/gastric cardiac adenocarcinoma[12]
20q13.2	1	6	51 568 862-51 993 797	424.9	ZNF2173, SUMO1P1, BCAS13	Esophageal adenocarcinoma[14], adenocarcinoma of the gastroesophageal junction[46]3, breast cancer[47], gastric adenocarcinoma[48], glioblastoma[49], various cancers[50]

¹Novel amplicon;

²Gene and references that are overexpressed when amplified in gastric cancer;

³Genes (and references) that are overexpressed when amplified in types of cancer other than gastric cancer;

⁴Underexpression has been reported in gastric cancer. SRO: Smallest region of overlap; N/A: Not available.